Cargando…
Assessing and managing medication overuse headache in Australian clinical practice
More than 3 million Australians are estimated to have migraine disorders, and over a quarter of a million Australians are estimated to have medication overuse headache (MOH). The personal, societal and economic burden of MOH is high. MOH impacts an individual’s ability to work or study, care for fam...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255228/ https://www.ncbi.nlm.nih.gov/pubmed/37304309 http://dx.doi.org/10.1136/bmjno-2023-000418 |
_version_ | 1785056820797112320 |
---|---|
author | Wijeratne, Tissa Jenkins, Bronwyn Stark, Richard J Sun-Edelstein, Christina |
author_facet | Wijeratne, Tissa Jenkins, Bronwyn Stark, Richard J Sun-Edelstein, Christina |
author_sort | Wijeratne, Tissa |
collection | PubMed |
description | More than 3 million Australians are estimated to have migraine disorders, and over a quarter of a million Australians are estimated to have medication overuse headache (MOH). The personal, societal and economic burden of MOH is high. MOH impacts an individual’s ability to work or study, care for family or themselves, culminating in poor quality of life. Accurate and timely diagnosis and treatment of MOH are imperative. Withdrawal failures and relapse rates are high in MOH. Treatment of MOH is aimed at ceasing medication overuse and reducing monthly migraine days with the aim of achieving a pattern of well-controlled episodic migraine. Current treatment approaches in routine practice include withdrawal with preventive treatment, withdrawal with optional preventive treatment in the subsequent weeks and preventive treatment without withdrawal. This viewpoint article provides an overview of managing MOH in Australian clinical practice, with a focus on the importance of patient education and the role of preventive treatment in supporting patients as they withdraw from acute migraine medication(s). |
format | Online Article Text |
id | pubmed-10255228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-102552282023-06-10 Assessing and managing medication overuse headache in Australian clinical practice Wijeratne, Tissa Jenkins, Bronwyn Stark, Richard J Sun-Edelstein, Christina BMJ Neurol Open Viewpoint More than 3 million Australians are estimated to have migraine disorders, and over a quarter of a million Australians are estimated to have medication overuse headache (MOH). The personal, societal and economic burden of MOH is high. MOH impacts an individual’s ability to work or study, care for family or themselves, culminating in poor quality of life. Accurate and timely diagnosis and treatment of MOH are imperative. Withdrawal failures and relapse rates are high in MOH. Treatment of MOH is aimed at ceasing medication overuse and reducing monthly migraine days with the aim of achieving a pattern of well-controlled episodic migraine. Current treatment approaches in routine practice include withdrawal with preventive treatment, withdrawal with optional preventive treatment in the subsequent weeks and preventive treatment without withdrawal. This viewpoint article provides an overview of managing MOH in Australian clinical practice, with a focus on the importance of patient education and the role of preventive treatment in supporting patients as they withdraw from acute migraine medication(s). BMJ Publishing Group 2023-05-31 /pmc/articles/PMC10255228/ /pubmed/37304309 http://dx.doi.org/10.1136/bmjno-2023-000418 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Viewpoint Wijeratne, Tissa Jenkins, Bronwyn Stark, Richard J Sun-Edelstein, Christina Assessing and managing medication overuse headache in Australian clinical practice |
title | Assessing and managing medication overuse headache in Australian clinical practice |
title_full | Assessing and managing medication overuse headache in Australian clinical practice |
title_fullStr | Assessing and managing medication overuse headache in Australian clinical practice |
title_full_unstemmed | Assessing and managing medication overuse headache in Australian clinical practice |
title_short | Assessing and managing medication overuse headache in Australian clinical practice |
title_sort | assessing and managing medication overuse headache in australian clinical practice |
topic | Viewpoint |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255228/ https://www.ncbi.nlm.nih.gov/pubmed/37304309 http://dx.doi.org/10.1136/bmjno-2023-000418 |
work_keys_str_mv | AT wijeratnetissa assessingandmanagingmedicationoveruseheadacheinaustralianclinicalpractice AT jenkinsbronwyn assessingandmanagingmedicationoveruseheadacheinaustralianclinicalpractice AT starkrichardj assessingandmanagingmedicationoveruseheadacheinaustralianclinicalpractice AT sunedelsteinchristina assessingandmanagingmedicationoveruseheadacheinaustralianclinicalpractice |